Michael Morse, MD, Duke Cancer Institute
Advertisement
Articles by Michael Morse, MD, Duke Cancer Institute
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Rusfertide for Polycythemia Vera
2
DESTINY-Breast05 Safety Analysis Clarifies ILD and Radiation Risks With T-DXd in HER2+ Breast Cancer
3
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
4
DAWN-303 Trial Set to Advance INCB161734 in First-Line KRAS G12D–Mutated Metastatic Pancreatic Cancer
5